Keywords
Last Name
Institution

PETER HOWARD JONES

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
DivisionMedicine-Athero & Lipoproteins
AddressOne Baylor Plaza
Houston TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Saeed A, Virani SS, Jones PH, Nambi V, Zoch D, Ballantyne CM. A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. J Clin Lipidol. 2017 May - Jun; 11(3):596-599. PMID: 28506382.
      View in: PubMed
    2. Jones PH, Bays HE, Chaudhari U, Pordy R, Lorenzato C, Miller K, Robinson JG. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. Am J Cardiol. 2016 Sep 14. PMID: 27729106.
      View in: PubMed
    3. Pokharel Y, Steinberg L, Chan W, Akeroyd JM, Jones PH, Nambi V, Nasir K, Petersen L, Ballantyne CM, Virani SS. A dataset to assess providers? knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Data Brief. 2016 Jun; 7:595-8. PMID: 27054163; PMCID: PMC4802420.
    4. Friedewald VE, Jones PH, Mason P, Roberts R, Weintraub H. The Editor's Round Table: Current Perspectives on Triglycerides and Atherosclerosis. Am J Cardiol. 2016 May 15; 117(10):1697-702. PMID: 27142496.
      View in: PubMed
    5. Bays H, Kothari SN, Azagury DE, Morton JM, Nguyen NT, Jones PH, Jacobson TA, Cohen DE, Orringer C, Westman EC, Horn DB, Scinta W, Primack C. Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surg Obes Relat Dis. 2016 Mar-Apr; 12(3):468-95. PMID: 27050404.
      View in: PubMed
    6. Pokharel Y, Steinberg L, Chan W, Akeroyd JM, Jones PH, Nambi V, Nasir K, Petersen L, Ballantyne CM, Virani SS. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis. 2016 Mar; 246:115-20. PMID: 26773472.
      View in: PubMed
    7. Bays HE, Jones PH, Orringer CE, Brown WV, Jacobson TA. National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol. 2016 Jan-Feb; 10(1 Suppl):S1-43. PMID: 26891998.
      View in: PubMed
    8. Bays HE, Jones PH, Jacobson TA, Cohen DE, Orringer CE, Kothari S, Azagury DE, Morton J, Nguyen NT, Westman EC, Horn DB, Scinta W, Primack C. Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. J Clin Lipidol. 2016 Jan-Feb; 10(1):15-32. PMID: 26892119.
      View in: PubMed
    9. Bays HE, Jones PH, Jacobson TA, Cohen DE, Orringer CE, Kothari S, Azagury DE, Morton J, Nguyen NT, Westman EC, Horn DB, Scinta W, Primack C. Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. J Clin Lipidol. 2016 Jan-Feb; 10(1):33-57. PMID: 26892120.
      View in: PubMed
    10. Virani SS, Pokharel Y, Steinberg L, Chan W, Akeroyd JM, Gowani SA, Kalra A, Polsani V, Miedema MD, Jones PH, Nambi V, Petersen LA, Ballantyne CM. Provider understanding of the 2013 ACC/AHA cholesterol guideline. J Clin Lipidol. 2016 May-Jun; 10(3):497-504.e4. PMID: 27206936.
      View in: PubMed
    11. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol. 2015 Nov-Dec; 9(6 Suppl):S1-S122.e1. PMID: 26699442.
      View in: PubMed
    12. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015 Mar-Apr; 9(2):129-69. PMID: 25911072.
      View in: PubMed
    13. Bays HE, Jones PH, Brown WV, Jacobson TA. National Lipid Association Annual Summary of Clinical Lipidology 2015. J Clin Lipidol. 2014 Nov-Dec; 8(6 Suppl):S1-36. PMID: 25523435.
      View in: PubMed
    14. Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C, Donahue S. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014 Oct; 37(10):597-604. PMID: 25269777; PMCID: PMC4282386.
    15. Pokharel Y, Nambi V, Martin SS, Hoogeveen RC, Nasir K, Khera A, Wong ND, Jones PH, Boone J, Roberts AJ, Ballantyne CM, Virani SS. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6. PMID: 25105582.
      View in: PubMed
    16. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014 Sep-Oct; 8(5):473-88. PMID: 25234560.
      View in: PubMed
    17. Tumova E, Sun W, Jones PH, Vrablik M, Ballantyne CM, Hoogeveen RC. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013; 2013:729515. PMID: 24455214; PMCID: PMC3880717.
    18. Friedewald VE, Ballantyne CM, Bays HE, Jones PH. The editor's roundtable: hypertriglyceridemia. Am J Cardiol. 2013 Oct 15; 112(8):1133-41. PMID: 24079443.
      View in: PubMed
    19. Vasudevan M, Tchoua U, Gillard BK, Jones PH, Ballantyne CM, Pownall HJ. Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol. 2013 Nov-Dec; 7(6):661-70. PMID: 24314365; PMCID: PMC4108339.
    20. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012 Dec; 1(6):e001800. PMID: 23316314; PMCID: PMC3540660.
    21. Negi SI, Brautbar A, Virani SS, Anand A, Polisecki E, Asztalos BF, Ballantyne CM, Schaefer EJ, Jones PH. A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. J Clin Lipidol. 2013 Jan-Feb; 7(1):82-7. PMID: 23351586.
      View in: PubMed
    22. Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44. PMID: 23312049.
      View in: PubMed
    23. Brautbar A, Virani SS, Belmont J, Nambi V, Jones PH, Ballantyne CM. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 2012 Mar; 53(3):556-60. PMID: 22236405; PMCID: PMC3276479.
    24. Negi SI, Steinberg L, Polsani VR, Gowani SA, Nambi V, Kumar V, Marinescu V, Jones PH, Petersen LA, Ballantyne CM, Virani SS. Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. J Clin Lipidol. 2012 Jan-Feb; 6(1):50-7. PMID: 22264574.
      View in: PubMed
    25. Brautbar A, Covarrubias D, Belmont J, Lara-Garduno F, Virani SS, Jones PH, Leal SM, Ballantyne CM. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42. PMID: 21889769.
      View in: PubMed
    26. Ballantyne CM, Jones PH, Kelly MT, Setze CM, Lele A, Thakker KM, Stolzenbach JC. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther. 2011 Feb; 25(1):59-67. PMID: 21416219; PMCID: PMC3070075.
    27. Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011 Feb 1; 107(3):387-92. PMID: 21257003; PMCID: PMC4713008.
    28. Jones PH. Management of obesity in the prevention of cardiovascular disease. Methodist Debakey Cardiovasc J. 2010 Nov-2011 Jan; 6(4):33-6. PMID: 21088657.
      View in: PubMed
    29. Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach JC, Sleep DJ. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J. 2010 Oct; 160(4):759-66. PMID: 20934572.
      View in: PubMed
    30. Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a). J Clin Lipidol. 2010 Jul-Aug; 4(4):240-7. PMID: 21122656.
      View in: PubMed
    31. Jones PH. Treating dyslipidemia in the high-risk patient. J Fam Pract. 2010 Feb; 59(2):E1. PMID: 20141719.
      View in: PubMed
    32. Jones PH. Update on lipids and C-reactive protein in acute and chronic coronary heart disease. Tex Heart Inst J. 2010; 37(3):307-8. PMID: 20548807; PMCID: PMC2879197.
    33. Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs. 2010; 10(3):175-86. PMID: 20524719.
      View in: PubMed
    34. Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84. PMID: 20136164.
      View in: PubMed
    35. Wu H, Perrard XD, Wang Q, Perrard JL, Polsani VR, Jones PH, Smith CW, Ballantyne CM. CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Arterioscler Thromb Vasc Biol. 2010 Feb; 30(2):186-92. PMID: 19910635; PMCID: PMC2830649.
    36. Polsani VR, Nambi V, Virani SS, Zoch D, Yang EY, Jones PH, Ballantyne CM. Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. J Clin Lipidol. 2009 Oct; 3(5):341-4. PMID: 21291832.
      View in: PubMed
    37. Jones PH, Davidson MH, Goldberg AC, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Lele A, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidol. 2009 Apr; 3(2):125-37. PMID: 21291802.
      View in: PubMed
    38. Jones PH. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am J Cardiol. 2008 Dec 22; 102(12A):41L-47L. PMID: 19084089.
      View in: PubMed
    39. van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, Jones PH, Schaefer EJ. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009 Apr; 50(4):730-9. PMID: 19043140; PMCID: PMC2656667.
    40. Otokozawa S, Ai M, Van Himbergen T, Asztalos BF, Tanaka A, Stein EA, Jones PH, Schaefer EJ. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis. 2009 Jul; 205(1):197-201. PMID: 19200542; PMCID: PMC4565182.
    41. Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, Buttler SM, Sleep DJ, Stolzenbach JC. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008 Dec; 2(6):426-35. PMID: 21291776.
      View in: PubMed
    42. Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15. PMID: 18996523.
      View in: PubMed
    43. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 16; 101(12A):51F-57F. PMID: 18549872.
      View in: PubMed
    44. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F. PMID: 18549871.
      View in: PubMed
    45. Jones PH, Farmer JA. Adjunctive interventions in myocardial infarction: the role of statin therapy. Curr Atheroscler Rep. 2008 Apr; 10(2):142-8. PMID: 18417069.
      View in: PubMed
    46. Polsani VR, Jones PH, Ballantyne CM, Nambi V. A case report of myopathy from consumption of red yeast rice. J Clin Lipidol. 2008 Feb; 2(1):60-2. PMID: 21291717.
      View in: PubMed
    47. Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008; 28(10):625-34. PMID: 18783301.
      View in: PubMed
    48. Davidson MH, Jones PH. Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Clin Drug Investig. 2008; 28(10):615-23. PMID: 18783300.
      View in: PubMed
    49. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol. 2008 Feb 1; 101(3):315-8. PMID: 18237592.
      View in: PubMed
    50. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, McGovern ME. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007 Jun; 192(2):432-7. PMID: 17239888.
      View in: PubMed
    51. Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol. 2007 Mar 1; 99(5):681-5. PMID: 17317371.
      View in: PubMed
    52. Bays H, Jones PH. Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag. 2007; 3(5):733-42. PMID: 18078024; PMCID: PMC2291317.
    53. Collins TC, Jones PH. Statin therapy: is the percent reduction or the attained low-density lipoprotein cholesterol level more important? Curr Atheroscler Rep. 2007 Jan; 9(1):10-7. PMID: 17169241.
      View in: PubMed
    54. Jones PH. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):133B-140B. PMID: 17307065.
      View in: PubMed
    55. Friedewald VE, Jones PH, Kaplan NM, Pool JL, Roberts WC. The editor's roundtable: concurrent hypertension and dyslipidemia. Am J Cardiol. 2007 Jan 1; 99(1):134-44. PMID: 17196477.
      View in: PubMed
    56. Jones PH. Dyslipidemia in older adults. Am J Geriatr Cardiol. 2006 Jul-Aug; 15(4):239-44. PMID: 16849890.
      View in: PubMed
    57. Jelesoff NE, Ballantyne CM, Xydakis AM, Chiou P, Jones PH, Guyton JR. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract. 2006 Mar-Apr; 12(2):159-64. PMID: 16690463.
      View in: PubMed
    58. Jones PH. Lipids: new guidelines, intensive treatment, and future directions. Tex Heart Inst J. 2006; 33(2):180-3. PMID: 16878620; PMCID: PMC1524680.
    59. Neal RC, Jones PH. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manag. 2006; 2(1):31-8. PMID: 17319467; PMCID: PMC1993974.
    60. Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr Atheroscler Rep. 2006 Jan; 8(1):76-84. PMID: 16455018.
      View in: PubMed
    61. Jones PH. Rationale for intensive statin treatment in high-risk patients. Prev Cardiol. 2006; 9(2):91-5. PMID: 16603827.
      View in: PubMed
    62. Vasudevan AR, Wu H, Xydakis AM, Jones PH, Smith EO, Sweeney JF, Corry DB, Ballantyne CM. Eotaxin and obesity. J Clin Endocrinol Metab. 2006 Jan; 91(1):256-61. PMID: 16263831.
      View in: PubMed
    63. Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr Cardiol Rep. 2005 Nov; 7(6):471-9. PMID: 16256018.
      View in: PubMed
    64. Vasudevan AR, Hamirani YS, Jones PH. Safety of statins: effects on muscle and the liver. Cleve Clin J Med. 2005 Nov; 72(11):990-3, 996-1001. PMID: 16315438.
      View in: PubMed
    65. Fordis M, King JE, Ballantyne CM, Jones PH, Schneider KH, Spann SJ, Greenberg SB, Greisinger AJ. Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA. 2005 Sep 7; 294(9):1043-51. PMID: 16145024.
      View in: PubMed
    66. Jones PH. Statins: the case for higher, individualized starting doses. Cleve Clin J Med. 2005 Sep; 72(9):811-6. PMID: 16193828.
      View in: PubMed
    67. Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, Smith EO, Nelson KW, Ballantyne CM. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem. 2005 Jul; 51(7):1102-9. PMID: 15976097.
      View in: PubMed
    68. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005 Feb 1; 95(3):360-6. PMID: 15670545.
      View in: PubMed
    69. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 1; 95(1):120-2. PMID: 15619408.
      View in: PubMed
    70. Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J. 2005 Jan; 149(1):e1. PMID: 15660024.
      View in: PubMed
    71. Xydakis AM, Guyton JR, Chiou P, Stein JL, Jones PH, Ballantyne CM. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol. 2004 Sep 15; 94(6):795-7. PMID: 15374793.
      View in: PubMed
    72. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004 Sep; 26(9):1388-99. PMID: 15531001.
      View in: PubMed
    73. Jones PH. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. Am Heart J. 2004 Jul; 148(1 Suppl):S9-13. PMID: 15211327.
      View in: PubMed
    74. Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, Nelson KW, Ballantyne CM. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004 Jun; 89(6):2697-703. PMID: 15181044.
      View in: PubMed
    75. Jones PH. Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment. Am J Med. 2004 Mar 22; 116 Suppl 6A:17S-25S. PMID: 15050188.
      View in: PubMed
    76. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'. Curr Opin Lipidol. 2004 Feb; 15(1):59-67. PMID: 15166810.
      View in: PubMed
    77. McPherson R, Jones PH. The metabolic syndrome and type 2 diabetes: role of the adipocyte. Curr Opin Lipidol. 2003 Dec; 14(6):549-53. PMID: 14624130.
      View in: PubMed
    78. Xydakis AM, Jones PH. Toxicity of antilipidemic agents: facts and fictions. Curr Atheroscler Rep. 2003 Sep; 5(5):403-10. PMID: 12911851.
      View in: PubMed
    79. Neal RC, Jones PH. Lipid-lowering: can ezetimibe help close the treatment gap? Cleve Clin J Med. 2003 Sep; 70(9):777-83. PMID: 14518572.
      View in: PubMed
    80. Jones PH. Atherosclerosis target of lipid-lowering therapy: is lower LDL cholesterol better? Am J Manag Care. 2003 Aug; Suppl:1, 4-5. PMID: 13678393.
      View in: PubMed
    81. Jones PH. Achieving cholesterol goals. Current and future drug therapies. Postgrad Med. 2003 Aug; 114(2 Suppl):14-21. PMID: 19667635.
      View in: PubMed
    82. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 Jul 15; 92(2):152-60. PMID: 12860216.
      View in: PubMed
    83. Jones PH. Cholesterol and coronary events. The current thinking. Postgrad Med. 2003 Apr; 113(4 Suppl):5-14. PMID: 19667618.
      View in: PubMed
    84. Xydakis AM, Jones PH. Use of Statins for Secondary Prevention. Curr Treat Options Cardiovasc Med. 2003 Feb; 5(1):63-73. PMID: 12686019.
      View in: PubMed
    85. Jones PH. Comparing HMG-CoA reductase inhibitors. Clin Cardiol. 2003 Jan; 26(1 Suppl 1):I15-20. PMID: 12539818.
      View in: PubMed
    86. McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003; 19(8):689-98. PMID: 14687438.
      View in: PubMed
    87. Case CC, Jones PH, Nelson K, O'Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002 Nov; 4(6):407-14. PMID: 12406040.
      View in: PubMed
    88. Jones PH. The power of statins: aggressive lipid lowering. Postgrad Med. 2002 Oct; 112(4 Suppl):23-30. PMID: 19667597.
      View in: PubMed
    89. Plana JC, Jones PH. The use of statins in acute coronary syndromes: the mechanisms behind the outcomes. Curr Atheroscler Rep. 2001 Sep; 3(5):355-64. PMID: 11487446.
      View in: PubMed
    90. Jones PH. Cholesterol: precursor to many lipid disorders. Am J Manag Care. 2001 Aug; 7(9 Suppl):S289-98. PMID: 11517815.
      View in: PubMed
    91. Jones PH. Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol. 2001 Apr 15; 87(8):1032-4. PMID: 11327075.
      View in: PubMed
    92. Hunninghake DB, McKenney JM, Gotto AM, Mehta JL, Jones PH. Roundtable discussion. Achieving more aggressive low-density lipoprotein cholesterol lowering. Am J Manag Care. 2000 Nov; 6(19 Suppl):S1008-16. PMID: 11187369.
      View in: PubMed
    93. Jones PH. Diet and pharmacologic therapy of obesity to modify atherosclerosis. Curr Atheroscler Rep. 2000 Jul; 2(4):314-20. PMID: 11122760.
      View in: PubMed
    94. Jones PH. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go? Drugs. 2000 May; 59(5):1127-35. PMID: 10852644.
      View in: PubMed
    95. Jones PH. The nature of the statins. Circulation. 2000 Feb 29; 101(8):E89. PMID: 10694539.
      View in: PubMed
    96. Jones PH. Web alert. Curr Cardiol Rep. 1999 Sep; 1(3):175-6. PMID: 11203285.
      View in: PubMed
    97. Jones PH. Fibrates and high-dose statins to prevent coronary heart disease events. Curr Cardiol Rep. 1999 Sep; 1(3):223-4. PMID: 10980845.
      View in: PubMed
    98. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JR, Gotto AM. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 1999 Feb 16; 99(6):736-43. PMID: 9989957.
      View in: PubMed
    99. von Bergmann K, Jones PH. Therapy and clinical trials. Curr Opin Lipidol. 1998 Dec; 9(6):519-20. PMID: 9868585.
      View in: PubMed
    100. Jones PH. Future of lipid-lowering trials: what else do we need to know? Am J Cardiol. 1998 Sep 24; 82(6A):32M-38M. PMID: 9766346.
      View in: PubMed
    101. Jones PH. Clinical diagnosis of lipid disorders. Clin Cornerstone. 1998 Jun-Jul; 1(1):15-30. PMID: 10682161.
      View in: PubMed
    102. Gordon BR, Kelsey SF, Dau PC, Gotto AM, Graham K, Illingworth DR, Isaacsohn J, Jones PH, Leitman SF, Saal SD, Stein EA, Stern TN, Troendle A, Zwiener RJ. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am J Cardiol. 1998 Feb 15; 81(4):407-11. PMID: 9485128.
      View in: PubMed
    103. Jones PH, von Bergmann K. Therapy and clinical trials. Curr Opin Lipidol. 1997 Dec; 8(6):329-31. PMID: 9412771.
      View in: PubMed
    104. Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol. 1997 Dec; 8(6):354-61. PMID: 9412776.
      View in: PubMed
    105. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ, Jones PH, West MS, Gould KL, Gotto AM. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997 Aug 1; 80(3):278-86. PMID: 9264419.
      View in: PubMed
    106. Davidson MH, Nawrocki JW, Weiss SR, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Am J Cardiol. 1997 Aug 1; 80(3):347-8. PMID: 9264433.
      View in: PubMed
    107. Jones PH, Pownall HJ, Patsch W, Herd JA, Farmer JA, Payton-Ross C, Kimball KT, Gotto AM, Morrisett JD. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. J Lipid Res. 1996 Jun; 37(6):1298-308. PMID: 8808764.
      View in: PubMed
    108. Jones PH. Treatment of dyslipidemias. Endocr Pract. 1996 Jan-Feb; 2(1):30-6. PMID: 15251559.
      View in: PubMed
    109. Jones PH. Trials of lipid-lowering therapy in primary prevention of coronary heart disease. Curr Opin Lipidol. 1995 Dec; 6(6):365-8. PMID: 8750249.
      View in: PubMed
    110. Jones PH, Gotto AM. Extending the benefit of lipid-regulating therapy to primary prevention. Am J Cardiol. 1995 Sep 28; 76(9):118C-121C. PMID: 7572680.
      View in: PubMed
    111. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995 May; 15(5):678-82. PMID: 7749881.
      View in: PubMed
    112. Jones PH. Low serum cholesterol increases the risk of noncardiovascular events: an antagonist viewpoint. Cardiovasc Drugs Ther. 1994 Dec; 8(6):871-4. PMID: 7742266.
      View in: PubMed
    113. Jones PH, Gotto AM. Prevention of coronary heart disease in 1994: evidence for intervention. Heart Dis Stroke. 1994 Nov-Dec; 3(6):290-6. PMID: 7850144.
      View in: PubMed
    114. Quion JA, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet. 1994 Aug; 27(2):94-103. PMID: 7955780.
      View in: PubMed
    115. Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM, Illingworth DR, Jones PH, Leitman SF, Prihoda JS, et al. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. Am J Cardiol. 1992 Oct 15; 70(11):1010-6. PMID: 1414897.
      View in: PubMed
    116. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM, Mantell G. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther. 1992 Sep-Oct; 14(5):708-17. PMID: 1468089.
      View in: PubMed
    117. Jones PH. A clinical overview of dyslipidemias: treatment strategies. Am J Med. 1992 Aug; 93(2):187-98. PMID: 1497016.
      View in: PubMed
    118. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, Cocanougher B, Jones PH, Young JB, Gotto AM. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 1992 May; 19(6):1315-21. PMID: 1564233.
      View in: PubMed
    119. Jones PH, Farmer JA, Cressman MD, McKenney JM, Wright JT, Proctor JD, Berkson DM, Farnham DJ, Wolfson PM, Colfer HT, et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol. 1991 Feb; 14(2):146-51. PMID: 1904333.
      View in: PubMed
    120. Jones PH. Lovastatin and simvastatin prevention studies. Am J Cardiol. 1990 Sep 18; 66(8):39B-43B. PMID: 2206035.
      View in: PubMed
    121. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA. 1988 Jul 8; 260(2):239-41. PMID: 3290520.
      View in: PubMed
    122. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988 Jan 7; 318(1):47-8. PMID: 3275892.
      View in: PubMed
    123. Ballantyne CM, Jones PH, Payton-Ross C, Patsch W, Short HD, Noon GP, Gotto AM, DeBakey ME, Young JB. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987 Aug; 19(4 Suppl 5):60-2. PMID: 3303569.
      View in: PubMed
    JONES's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _